Open Access. Powered by Scholars. Published by Universities.®
Biomedical Engineering and Bioengineering Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Biomedical Engineering and Bioengineering
Mechanism Of Therapeutic Efficacy Of New Drugs In Glioblastoma, Firas Hameed Khathayer
Mechanism Of Therapeutic Efficacy Of New Drugs In Glioblastoma, Firas Hameed Khathayer
Theses and Dissertations
Glioblastoma is the most malignant and prevalent brain tumor in adults. It can grow and spread quickly causing harm to brain health. The deregulation of epigenetic mechanisms is considered the main agent in the developing of GBM. One of the enzymes involved in epigenetic alternation and cancer development are histone deacetylases enzyme (HDAC) by removal acetyl group from histone and create condensed chromatin that suppresses transcription gene to histone and non-histone proteins involved in tumorigenesis. Histone deacetylase inhibitors (HADCi) are the most common therapeutic methods for many types of cancer treatments. In the present study, we used relative HDAC inhibitor …
Cis-Resveratrol Upregulates Tyrosyl-Trna Synthetase And Inhibits The Proliferation Of Select Breast Cancer Cell Lines, Marion Cone Hope Iii
Cis-Resveratrol Upregulates Tyrosyl-Trna Synthetase And Inhibits The Proliferation Of Select Breast Cancer Cell Lines, Marion Cone Hope Iii
Theses and Dissertations
Breast cancer is one of the most commonly occurring cancers in women. 70% of breast cancer patients express ERα and are treated with tamoxifen (Tam), a drug that is used to directly target ERα. However, 20-30% of cancer patients develop a resistance to Tam. This resistance leads to a worse prognosis and other treatments such as DNA damaging drugs or radiation to eliminate these cells. Resveratrol (RSV) is a polyphenolic- compound found in plants such as grapes and hellebore and is known to evoke anti-cancer effects. While natural resveratrol exists as a mixture of both cis- and trans- isomers, so …